Benito Lopez
Medical · Edinburg, TXNPI 1033640685
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (47.7%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by Abbott at 25.1% of the total. 2025 is the largest year on record at $41,971, 8.7 times the $4,837 reported in 2021. Among medical clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,145 payments — averaging $61.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$18K
- Corcept Therapeutics$11K
- Insulet Corporation$10K
- Intuity Medical Inc$7K
- Novo Nordisk$2K
- Medtronic$2K
- plus $20K from 54 others
What the payments were for
- Speaking & faculty fees$33,59348%
- Travel & lodging$6,4539%
- Food & beverage$30,04443%
- Education$3120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FREESTYLE LIBRE 3$16,355
- Korlym$9,193
- Omnipod$8,896
- Pogo Automatic Blood Glucose Monitoring System$7,037
- MINIMED 780G$1,317
- DEXCOM G6 TRANSMITTER$702
- BREZTRI$580
- AFREZZA$501
- iLet Bionic Pancreas$440
- FreeStyle Libre$406
- EVERSENSE E3 SENSOR KIT - RETAIL$390
- NEXLIZET$351
- NEXLETOL$351
- Xhance$349
- Qutenza$344
- Ozempic$336
- MOUNJARO$247
- KRYSTEXXA$231
- EVERSENSE 365 SENSOR KIT (RETAIL)$229
- MYCAPSSA$167
How this compares
$70,402 in reported general payments places this provider in the 95th percentile of 1,490 medical providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KorlymMifepristone | 162 | $5,290,620 |
| OzempicSemaglutide | 345 | $511,537 |
| MounjaroTirzepatide | 301 | $391,936 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 157 | $174,615 |
| JardianceEmpagliflozin | 135 | $164,501 |
| TrulicityDulaglutide | 59 | $105,858 |
| Tresiba Flextouch U-200Insulin Degludec | 151 | $103,174 |
| QutenzaCapsaicin/Skin Cleanser | 28 | $97,613 |
| KerendiaFinerenone | 78 | $87,320 |
| FarxigaDapagliflozin Propanediol | 52 | $66,648 |
| TymlosAbaloparatide | 22 | $66,097 |
| RybelsusSemaglutide | 47 | $61,027 |
| Xigduo XrDapaglifloz Propaned/Metformin | 75 | $55,682 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 86 | $51,835 |
| AfrezzaInsulin Regular, Human | 25 | $48,267 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Corcept TherapeuticsKorlym | $10,938 | $5,290,620162 claims |
| Novo NordiskOzempic, Rybelsus, Fiasp | $2,481 | $582,261405 claims |
| Lilly USA, LLCMounjaro, Trulicity | $1,296 | $497,794360 claims |
| Boehringer IngelheimSynjardy Xr, Jardiance, Trijardy Xr, Glyxambi, Tradjenta | $719 | $413,116388 claims |
| BayerKerendia | $534 | $87,32078 claims |
| AstraZenecaFarxiga | $1,950 | $66,64852 claims |
| Radius Health, Inc.Tymlos | $551 | $66,09722 claims |
| Mannkind CorporationAfrezza | $1,416 | $48,26725 claims |
| AmgenEvenity (2 Syringes) | $1,082 | $39,66016 claims |
| MerckJanuvia | $165 | $20,51616 claims |
| AbbVieLinzess | $516 | $14,08119 claims |
| Esperion Therapeutics, Inc.Nexlizet | $663 | $8,55515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,490 medical providers in Texas.
Other medical in Edinburg
- Mark DavisFort Worth$1M
- Joey Dixon-JulianBoerne$458K
- Terry FaleyeKingwood$243K
- Kimberly PoarchDallas$166K
- Erin DuhaimeDallas$150K
- Shakira CabreraSan Antonio$116K
- Danny DeckardDallas$101K
- Courtney AldridgeSan Antonio$89K
- Janine ShinnDallas$84K
- Radha BernanderKaty$74K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.